Litcius/Paper detail

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges

Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, Vasilios Kotsis, Rohit Loomba, Arun J. Sanyal, Christos S. Mantzoros

2024Metabolism138 citationsDOIOpen Access PDF

Topics & Concepts

SteatohepatitisMedicineDrugIntensive care medicineInternal medicinePharmacologyFatty liverDiseaseLiver Disease Diagnosis and TreatmentMetabolism, Diabetes, and CancerDiet, Metabolism, and Disease
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges | Litcius